Israel’s Compugen discovers biomarker for ovarian cancer Israeli company Compugen
has announced the discovery and experimental verification of a molecular biomarker candidate for the diagnosis of ovarian cancer.
The biomarker, CGEN-327, is a previously unknown splice variant of the HE4 (Human Epididymis Protein 4) gene, which is a known biomarker for ovarian cancer. CGEN-327 exists in ovary tissues, and can be found at higher levels in ovarian cancer tissues.
Compugen, which plans to patent its discovery, has now entered into a research and license option agreement for the product candidate with a leading diagnostic company, which has not yet been named.
Tel Aviv based Compugen began its search for this biomarker after being approached by a company that develops and commercializes immunoassay panels for rapid diagnosis of challenging diseases.